Abstracts may be submitted for oral and poster presentations for the following topics:
| 1. PATHOGENESIS OF ATHEROSCLEROSIS |
| 1.1 Endothelial cell function and biology |
| 1.2 Smooth muscle cell biology |
| 1.3 Macrophages in lipid metabolism and atherosclerosis |
| 1.4 Inflammation, immunity and infection in atherosclerosis |
| 1.5 Extracellular matrix and calcification |
| 1.6 Vascular biology of the arterial wall: Miscellaneous |
| 1.7 Imaging technology |
| 1.8 Platelets, thrombosis and atherosclerosis |
| 1.9 Aortic valve stenosis |
| 1.10 Clonal Haematopoiesis |
| 1.11 Plaque remodelling |
| 1.12 Other |
| 2. LIPIDS AND LIPOPROTEINS |
| 2.1 Lp(a) |
| 2.2 TG rich lipoproteins metabolism and lipases |
| 2.3 HDL |
| 2.4 Lipoprotein receptors |
| 2.5 Bile acids |
| 2.6 Cholesterol efflux and reverse cholesterol transport |
| 2.7 Lipidomics |
| 2.8 Cellular lipid metabolism and lipid droplets |
| 2.9 Lipid and lipoprotein metabolism |
| 2.10 Modified lipoproteins |
| 2.11 Liver metabolism and steatosis |
| 2.12 Adipose tissue biology and pathology |
| 2.13 Other |
| 3. DYSLIPIDEMIA AND RISK FACTORS |
| 3.1 Epidemiology of cardiovascular diseases and risk factors |
| 3.2 Epidemiology of dyslipidemias |
| 3.3 Diabetes, insulin sensitivity and resistance |
| 3.4 Adipose tissue homeostasis |
| 3.5 Inherited dyslipidemias |
| 3.6 Gender and cardiovascular risk |
| 3.7 Environmental risk factors |
| 3.8 Novel risk factors and biomarkers |
| 3.9 Epidemiology of socioeconomic and psychosocial risk factors |
| 3.10 Coagulation |
| 3.11 Gut microbiome |
| 3.12 Gene editing technology |
| 3.13 Genomics, GWAS and population genetics; Mendelian randomization |
| 3.14 Epigenetics and microRNA |
| 3.15 Gene-Environment interactions |
| 3.16 Other |
| 4. CLINICAL VASCULAR DISEASE |
| 4.1 Coagulation and Thrombosis |
| 4.2 Endothelial dysfunction; Clinical assessment |
| 4.3 NASH and other ectopic lipid diseases |
| 4.4 Chronic kidney disease and nephropathies |
| 4.5 Diabetes; macro- and microangiopathies |
| 4.6 Aneurysms and other non-atherosclerotic arteriopathies |
| 4.7 Nutrition, nutraceuticals |
| 4.8 Bariatric surgery |
| 4.9 Lipid-lowering therapies |
| 4.10 Anti-thrombotic therapies |
| 4.11 Anti-inflammatory therapies |
| 4.12 Prevention and treatment of cardiovasculardisease; miscellaneous |
| 4.13 New lipid lowering therapies |
| 4.14 Other |
